Pulsenmore Ltd.

Key People

• Dr. Elazar Sonnenschein - Founder, CEO & Director
• Ms. Mira Altmark-Sofer - Vice President of Marketing
• Ms. Hagar Spits - CEO of Pulsenmore Americas LLC
• Mr. Minelu Sonnenschein - Vice President of Hardware
• Mr. Meir Shmouely - Vice President of Software
• Eran Hirsh - Chief Financial Officer
• Dan Gus - Director of Operations & Capital Markets
• Mr. Michael Hamelsdorf - General Counsel & Company Secretary
• Prof. Israel Meizner - Chief Medical Officer & Member of Scientific Advisory Committee
• Mr. Len Farris - Chief Commercial Officer

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology and device companies.

Dr. Elazar Sonnenschein, the founder and CEO, has a history of founding successful medical device companies, including Medigus. The board includes individuals with significant experience in medical technology and healthcare management, such as Jonathan Adereth, former President and CEO of Elscint, and Prof. Anat Loewenstein, a prominent figure in ophthalmology. This collective expertise enhances the company's strategic direction and operational execution.

Clinical Need

Aspect: Very Strong
Summary: Pulsenmore addresses a significant need for accessible prenatal care through home ultrasound technology.

The Pulsenmore ES device enables expectant mothers to perform ultrasound scans at home, reducing the need for frequent hospital visits. This innovation is particularly valuable in regions with limited access to healthcare facilities, addressing a critical gap in prenatal care. The partnership with Clalit Health Services to deliver 25,000 home ultrasound devices underscores the strong demand and clinical relevance of Pulsenmore's solution.

Competition

Aspect: First mover
Summary: Pulsenmore is a pioneer in the home ultrasound market, with limited direct competition.

Pulsenmore's development of a home-use ultrasound device that integrates with smartphones is a novel approach in the medical device industry. While traditional ultrasound devices are available, the convenience and accessibility of Pulsenmore's solution set it apart. The strategic investment from GE Healthcare further validates its unique position in the market.

Technical Challenge

Aspect: Moderate
Summary: Developing a user-friendly, accurate home ultrasound device presents moderate technical challenges.

The integration of ultrasound technology with smartphones requires careful design to maintain image quality and diagnostic reliability. Additionally, creating an intuitive user interface for expectant mothers without medical training adds complexity. However, Pulsenmore's existing product and regulatory approvals indicate successful navigation of these challenges.

Patent

Aspect: Very Strong
Summary: Pulsenmore holds a robust patent portfolio, enhancing its competitive edge.

With over 70 patents filed and 15 granted, Pulsenmore has secured intellectual property rights that safeguard its technology from competitors. This strong patent portfolio not only reinforces the company's valuation but also provides leverage in strategic partnerships and potential licensing opportunities.

Financing

Aspect: Strategics
Summary: Pulsenmore has secured substantial funding from strategic investors, including GE Healthcare.

The company raised approximately $42 million in its IPO on the Tel Aviv Stock Exchange in 2021 and received a $21 million investment from GE Healthcare. These funds support product development, regulatory approvals, and market expansion. The involvement of strategic investors also offers valuable industry insights and potential distribution channels.

Regulatory

Aspect: 510k/PMA
Summary: Pulsenmore has achieved multiple regulatory approvals, facilitating market entry.

The Pulsenmore ES device has received regulatory approvals in Europe (CE), the UK, Switzerland, Australia (TGA), Brazil (ANVISA), and Israel (AMAR). In the U.S., the device is currently limited to investigational use, indicating ongoing efforts toward FDA clearance. These approvals demonstrate compliance with international standards and support global market penetration.

Opportunity Rollup

Odds of Success

3.75

Peak Market Share

4.75

Segment CAGR

2.9%

Market Segment

Diagnostic Imaging

Market Sub Segment

Home Ultrasound Devices

Key Takeaway

Pulsenmore's innovative home ultrasound technology addresses a significant clinical need, supported by a strong team, strategic partnerships, and a robust patent portfolio, positioning the company for substantial growth in the evolving telehealth landscape.